ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory disease affecting ~ 10% of adults and ~ 20% of children globally. Many patients with moderate-to-severe AD receiving systemic therapies, including biologics and Janus kinase (JAK) inhibitors, fail to reach or maintain treatment goals due to lack of durable response or safety/tolerability issues. Rocatinlimab is a T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. ROCKET, a large, global phase 3 program of eight clinical trials (NCT05398445; NCT05651711; NCT05724199; NCT05899816; NCT05704738; NCT05633355; NCT05882877; NCT06224192), will evaluate the efficacy, durability of response, and long-term safety of rocatinlimab as monotherapy and combination therapy in adult and adolescent patients with moderate-to-severe AD with or without prior exposure to biologics or systemic JAK inhibitors.
Authors
- Eric L. Simpson (ORCID: https://orcid.org/0000-0003-0853-0252)
- Greg Kricorian (ORCID: https://orcid.org/0000-0002-9419-9836)
- Lynda Spelman (ORCID: https://orcid.org/0000-0002-7330-4713)
- Jana Hercogová (ORCID: https://orcid.org/0000-0003-1702-5995)
- Kenji Kabashima (ORCID: https://orcid.org/0000-0002-0773-0554)
- Emma Guttman‐Yassky (ORCID: https://orcid.org/0000-0002-9363-324X)
- Robert Bissonnette (ORCID: https://orcid.org/0000-0001-5927-6587)
- Hirotaka Mano
- Prista Charuworn (ORCID: https://orcid.org/0000-0002-7284-5251)
- Margitta Worm (ORCID: https://orcid.org/0000-0002-3449-1245)
- Takahiro Arai (ORCID: https://orcid.org/0000-0003-3153-5377)
- Andrea Wang (ORCID: https://orcid.org/0000-0002-9683-2498)
- Paula Carolina Luna (ORCID: https://orcid.org/0000-0002-8002-4234)
- Lawrence F. Eichenfield (ORCID: https://orcid.org/0000-0002-2760-0474)
- Ehsanollah Esfandiari
Institutions
- Amgen (United States) (US)
- Oregon Health & Science University (US)
- Kyoto University (JP)
- University of California San Diego (US)
- Rady Children's Hospital-San Diego (US)
- Kyowa Kirin International (United Kingdom) (GB)
- Innovaderm (Canada) (CA)
- Hospital Alemán (AR)
- Kyowa Kirin (France) (FR)
- Veracity Clinical Research (AU)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1080/1750743x.2025.2464528
- Citations
- 10
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 20.05
Funders
- Amgen